|
시장보고서
상품코드
2091371
갈색세포종 시장 규모, 점유율, 성장 분석 : 치료법별, 진단별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Pheochromocytoma Market Size, Share, and Growth Analysis, By Treatment Type (Surgery, Drug Therapy), By Diagnosis Type (Biochemical Tests, Imaging Tests), By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 갈색세포종 시장 규모는 2024년에 15억 9,000만 달러로 평가되었으며, 2025년 16억 8,000만 달러에서 2033년까지 26억 4,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 5.8%로 성장할 것으로 전망됩니다.
세계 갈색세포종 시장은 희귀질환 인센티브를 통해 혁신적인 치료법 개발을 촉진하는 규제 당국의 지원에 힘입어 눈부신 성장을 이루고 있습니다. 희귀질환 치료제(오르판 드럭) 지정을 통해 개발 기업에는 심사 절차의 신속화 및 세제상의 우대 조치가 제공되며, 재무적 위험이 경감됨에 따라 카테콜아민 합성 억제제 등의 신약 도입이 촉진되고 있습니다. 그 결과, 종양 내 노르에피네프린 방출을 억제하는 약물에 대한 유망한 임상시험이 다수 진행 중이며, 외과적 시술에 대한 대안이 제시되고 있습니다. 또한, AI 기술은 이미지 데이터를 분석하여 조기 발견을 도모하고, 유전체 변이를 특정하여 맞춤형 치료를 실현하며, 치료 방침 수립을 효율화함으로써 진단과 치료 모두를 향상시키고 있습니다. 이러한 발전이 환자의 예후와 의료 서비스의 효율성을 개선함에 따라, 추가 투자를 촉진하고 시장 성장을 뒷받침함으로써 새로운 치료법의 도입 확대로 이어지고 있습니다.
세계 갈색세포종 시장의 성장요인
세계 갈색세포종 시장의 주요 성장 요인 중 하나는 내분비 질환의 유병률 증가와 더불어, 이에 대한 인식 제고 및 진단 기술의 발전입니다. 의료진의 갈색세포종에 대한 지식이 깊어짐에 따라 조기 진단과 치료가 우선시되고 있으며, 이는 환자의 예후 개선으로 이어지고 있습니다. 또한, 영상 진단 기술과 바이오마커 규명 분야의 혁신으로 인해 이 희귀 종양의 조기 발견 및 경과 관찰이 개선되면서, 전문적인 치료법에 대한 수요가 증가하고 있습니다. 맞춤형 의료와 환자 개개인에 맞춘 치료법에 대한 관심이 높아지고 있는 점도, 갈색세포종 환자에게 특화된 효과적인 약물 및 치료 전략의 개발을 촉진하여 시장 성장을 더욱 뒷받침하고 있습니다.
세계 갈색세포종 시장의 제약요인
세계 갈색세포종 시장의 주요 시장 제약요인은 의료 종사자 및 일반 대중 사이에서 이 질환에 대한 인식과 이해가 제한적이라는 점입니다. 갈색세포종은 적시에 진단 및 치료가 이루어지지 않으면 심각한 건강상의 합병증을 유발할 가능성이 있는 희귀 종양입니다. 이러한 인식 부족은 진단 지연이나 보고 건수의 부족으로 이어지며, 그 결과 효과적인 치료법이나 선별 검사 도구에 대한 수요를 저해하고 있습니다. 게다가 이 질환의 복잡성에 더해 전문적인 치료법의 필요성까지 겹치면서, 갈색세포종을 관리하려는 의료 서비스 제공자의 수가 더욱 제한되고 있으며, 이는 시장 전체의 성장에 영향을 미치고 있습니다.
세계 갈색세포종 시장의 동향
세계 갈색세포종 시장에서는 정밀 영상 진단 기술 도입을 향한 뚜렷한 추세가 나타나고 있으며, 이 희귀 종양의 진단 및 치료 수준이 크게 향상되고 있습니다. 의료 종사자들은 혁신적인 방사성 추적자를 이용한 PET/CT 스캔 등, 조기 발견과 정확한 위치 파악을 가능하게 하는 첨단 영상 진단법을 점점 더 선호하고 있습니다. 이러한 발전은 진단의 불확실성을 줄일 뿐만 아니라, 치료 과정을 신속하게 하고, 협력형 진료 모델의 추진으로도 이어지고 있습니다. 또한, 비침습적 치료에 중점을 두는 방침은 의사와 보험사 양측의 지지를 얻고 있습니다. 이러한 기법은 불필요한 개입을 최소화함으로써 비용 절감으로 이어질 가능성이 있기 때문입니다. 그 결과, 영상 진단 기업과 전문 검사 기관은 연구 제휴를 강화하고, 타겟을 명확히 한 홍보 활동을 통해 이처럼 증가하는 수요에 부응하기 위해 서비스 체계를 확충하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 갈색세포종 시장 규모 : 치료 유형별
세계의 갈색세포종 시장 규모 : 진단 유형별
세계의 갈색세포종 시장 규모 : 최종사용자별
세계의 갈색세포종 시장 규모 : 유통 채널별
세계의 갈색세포종 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Pheochromocytoma Market size was valued at USD 1.59 Billion in 2024 and is poised to grow from USD 1.68 Billion in 2025 to USD 2.64 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).
The global pheochromocytoma market is experiencing notable growth driven by regulatory support for rare-disease incentives, which promote the development of innovative treatments. The orphan-drug designation provides developers with expedited review pathways and tax benefits that reduce financial risks, facilitating the introduction of new agents, such as catecholamine-synthesis inhibitors. This has resulted in an enriched pipeline with promising clinical trials for drugs that lower intra-tumoral norepinephrine release, presenting alternatives to surgical interventions. Furthermore, AI technologies enhance both diagnosis and treatment by analyzing imaging data for early detection, identifying genomic mutations for personalized therapies, and streamlining treatment recommendations. As these advancements improve patient outcomes and healthcare efficiency, they stimulate further investment and propel market growth, leading to increased adoption of new therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pheochromocytoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pheochromocytoma Market Segments Analysis
Global pheochromocytoma market is segmented by treatment type, diagnosis type, end user, distribution channel and region. Based on treatment type, the market is segmented into Surgery, Drug Therapy, Radiopharmaceutical Therapy, Targeted Therapy and Others. Based on diagnosis type, the market is segmented into Biochemical Tests, Imaging Tests and Genetic Testing. Based on end user, the market is segmented into Hospitals, Specialty Endocrinology Centers, Oncology Centers and Academic & Research Institutes. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pheochromocytoma Market
One of the key market drivers for the global pheochromocytoma market is the increasing prevalence of endocrine disorders coupled with growing awareness and advancements in diagnostic technologies. As healthcare professionals become more knowledgeable about pheochromocytoma, timely diagnoses and treatments are prioritized, leading to improved patient outcomes. Additionally, innovations in imaging techniques and biomarker identification enhance early detection and monitoring of this rare tumor, driving demand for specialized treatment options. The rising focus on personalized medicine and tailored therapies further propels market growth by encouraging the development of effective drugs and care strategies specifically for pheochromocytoma patients.
Restraints in the Global Pheochromocytoma Market
A significant market restraint for the global pheochromocytoma market is the limited awareness and understanding of the condition among healthcare professionals and the general public. Pheochromocytoma is a rare tumor that can lead to serious health complications if not diagnosed and treated timely. This lack of awareness results in delayed diagnoses and underreporting, which hampers the demand for effective therapies and screening tools. Additionally, the complexity of the disorder, coupled with the need for specialized treatment options, further limits the availability of healthcare providers willing to engage in the management of pheochromocytoma, impacting overall market growth.
Market Trends of the Global Pheochromocytoma Market
The Global Pheochromocytoma market is witnessing a notable trend towards the adoption of precision imaging techniques, significantly enhancing the diagnosis and treatment of this rare tumor. Healthcare professionals increasingly favor advanced imaging modalities, such as PET/CT scans with innovative radiotracers, which facilitate earlier detection and precise localization. This evolution not only mitigates diagnostic uncertainty but also expedites the treatment process and encourages collaborative care models. Additionally, the emphasis on non-invasive procedures resonates with both physicians and payers, as these methods potentially reduce costs by minimizing unnecessary interventions. Consequently, imaging companies and specialized laboratories are ramping up research partnerships and expanding their service capabilities to cater to this rising demand through targeted outreach initiatives.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Pheochromocytoma Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Surgery
- Drug Therapy
- Alpha-Adrenergic Blockers
- Beta-Adrenergic Blockers
- Tyrosine Hydroxylase Inhibitors
- Radiopharmaceuticals
- Others
- Radiopharmaceutical Therapy
- Targeted Therapy
- Others
Global Pheochromocytoma Market Size by Diagnosis Type & CAGR (2026-2033)
- Market Overview
- Biochemical Tests
- Imaging Tests
- Genetic Testing
Global Pheochromocytoma Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Endocrinology Centers
- Oncology Centers
- Academic & Research Institutes
Global Pheochromocytoma Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
Global Pheochromocytoma Market Size & CAGR (2026-2033)
- North America (Treatment Type, Diagnosis Type, End User, Distribution Channel)
- US
- Canada
- Europe (Treatment Type, Diagnosis Type, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Diagnosis Type, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Diagnosis Type, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Diagnosis Type, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Lantheus Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Telix Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE HealthCare Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ITM Isotope Technologies Munich SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fusion Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RayzeBio, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clarity Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Blue Earth Therapeutics Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jubilant Radiopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Perspective Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
